We have an industry-leading pipeline of six potential medicines, including five compounds in Phase II or Phase III development, all of which have achieved human proof-of-concept. Altogether we currently have 16 compounds under investigation for development as potential new HIV treatments.
Clinical development pipeline
Product | Class | Phase |
|---|
| 1349572 (‘572)* (dolutegravir) |
Integrase inhibitor |
III |
| '572-Trii (dolutegravir+abacavir/lamivudine) |
Integrase inhibitor + NRTI Single Tablet regimen |
III |
| Lersivirine |
NNRTI |
IIb |
| 1265744* |
Integrase inhibitor |
IIa |
*Shionogi-ViiV Healthcare LLC
In addition, ViiV Healthcare pursues its preclinical pipeline through its relationship with the preclinical GSK and Pfizer R&D groups.